

## See List of Applications

#### SUPPLEMENT APPROVAL

Tolmar, Inc. Attention: Renu Gambhir, PhD Senior Director, Regulatory Affairs 701 Centre Avenue Fort Collins. CO 80526

Dear Dr. Gambhir:

Please refer to your supplemental New Drug Application(s) (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), and all amendments, for the following products:

| Supplemental Application | Product Information   | Submit Date       | FDA Received Date |
|--------------------------|---|-------------------|-------------------|
| NDA 021343/S-052         | Eligard (leuprolide acetate) for injectable suspension, 7.5 mg  | December 19, 2023 | December 19, 2023 |
| NDA-021379/S-055         | Eligard (leuprolide acetate) for injectable suspension, 22.5 mg | December 19, 2023 | December 19, 2023 |
| NDA-021488/S-050         | Eligard (leuprolide acetate) for injectable suspension, 30 mg   | December 19, 2023 | December 19, 2023 |
| NDA-021731/S-052         | Eligard (leuprolide acetate) for injectable suspension, 45 mg   | December 19, 2023 | December 19, 2023 |

These Prior Approval supplemental new drug applications provide for revisions to the Eligard carton and tray labels to emphasize the location of the co-packaged needle provided.

# **APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling and with minor editorial revisions reflected in the enclosed labeling.

#### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(I)] in structured product labeling (SPL) format using

the FDA automated drug registration and listing system (eLIST), as described at <a href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm">http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm</a>. Content of labeling must be identical to, except with the revisions indicated, the enclosed labeling (text for the perscribing information, and instructions for use) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at <a href="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/GuidanceS/UCM072392.pdf</a>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions indicated above approved in these supplemental applications, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **CARTON AND CONTAINER LABELS**

Submit final printed carton and container labels that are identical to enclosed carton and container labels and carton and container labels submitted on December 19, 2023, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission "Product Correspondence – Final Printed Carton and Container Labels for approved NDA 021343/S-052, NDA-021379/S-055, NDA-021488/S-050 and NDA-021731/S-052." Approval of this submission by FDA is not required before the labeling is used.

#### REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, , contact Utkarsh Desai, Regulatory Business Process Manager, at Utkarsh.Desai@fda.hhs.gov .


Sincerely,

{See appended electronic signature page}

Ramesh Raghavachari, Ph.D.
Supervisor
Division of Product Quality Assessment IV
Office of Product Quality Assessment I
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

# Enclosure(s):

- Content of Labeling
  - Prescribing Information
  - Instructions For Use
- Carton and Container Labeling



Digitally signed by Ramesh Raghavachari

Date: 5/21/2024 04:21:29PM

GUID: 502d0913000029f375128b0de8c50020